TWI602573B - 溶酶體酵素之腦脊髓膜內遞送及其醫療用途 - Google Patents

溶酶體酵素之腦脊髓膜內遞送及其醫療用途 Download PDF

Info

Publication number
TWI602573B
TWI602573B TW100122534A TW100122534A TWI602573B TW I602573 B TWI602573 B TW I602573B TW 100122534 A TW100122534 A TW 100122534A TW 100122534 A TW100122534 A TW 100122534A TW I602573 B TWI602573 B TW I602573B
Authority
TW
Taiwan
Prior art keywords
administration
brain
dose
tissue
animals
Prior art date
Application number
TW100122534A
Other languages
English (en)
Chinese (zh)
Other versions
TW201206465A (en
Inventor
柏里克斯 加萊斯
潘金
簡 鮑威爾
勞倫斯 恰爾納斯
湯瑪斯 麥考利
德瑞沙 莉亞 萊特
理查 菲佛
札赫拉 夏若克
Original Assignee
舒爾人類基因療法公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45352777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI602573(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 舒爾人類基因療法公司 filed Critical 舒爾人類基因療法公司
Publication of TW201206465A publication Critical patent/TW201206465A/zh
Application granted granted Critical
Publication of TWI602573B publication Critical patent/TWI602573B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
TW100122534A 2010-06-25 2011-06-27 溶酶體酵素之腦脊髓膜內遞送及其醫療用途 TWI602573B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09

Publications (2)

Publication Number Publication Date
TW201206465A TW201206465A (en) 2012-02-16
TWI602573B true TWI602573B (zh) 2017-10-21

Family

ID=45352777

Family Applications (9)

Application Number Title Priority Date Filing Date
TW100122534A TWI602573B (zh) 2010-06-25 2011-06-27 溶酶體酵素之腦脊髓膜內遞送及其醫療用途
TW105115109A TW201701899A (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送乙醯肝素ｎ-硫酸酯酶之方法及組合物
TW109118555A TWI790444B (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送芳基硫酸酯酶a之方法及組合物
TW100122529A TW201212936A (en) 2010-06-25 2011-06-27 Methods and compositions for intrathecal delivery of Alpha N-acetyglucosaminidase
TW106135183A TWI669128B (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送艾杜糖醛酸鹽(iduronate)-2-硫酸酯酶之方法及組合物
TW106108970A TWI609694B (zh) 2010-06-25 2011-06-27 溶酶體酵素之腦脊髓膜內遞送及其醫療用途
TW112102995A TWI876260B (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送芳基硫酸酯酶a之方法及組合物
TW113122692A TW202506172A (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送芳基硫酸酯酶a之方法及組合物
TW106127273A TWI698252B (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送芳基硫酸酯酶a之方法及組合物

Family Applications After (8)

Application Number Title Priority Date Filing Date
TW105115109A TW201701899A (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送乙醯肝素ｎ-硫酸酯酶之方法及組合物
TW109118555A TWI790444B (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送芳基硫酸酯酶a之方法及組合物
TW100122529A TW201212936A (en) 2010-06-25 2011-06-27 Methods and compositions for intrathecal delivery of Alpha N-acetyglucosaminidase
TW106135183A TWI669128B (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送艾杜糖醛酸鹽(iduronate)-2-硫酸酯酶之方法及組合物
TW106108970A TWI609694B (zh) 2010-06-25 2011-06-27 溶酶體酵素之腦脊髓膜內遞送及其醫療用途
TW112102995A TWI876260B (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送芳基硫酸酯酶a之方法及組合物
TW113122692A TW202506172A (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送芳基硫酸酯酶a之方法及組合物
TW106127273A TWI698252B (zh) 2010-06-25 2011-06-27 於腦脊髓膜內遞送芳基硫酸酯酶a之方法及組合物

Country Status (24)

Country Link
US (17) US9814764B2 (cg-RX-API-DMAC7.html)
JP (22) JP6250616B2 (cg-RX-API-DMAC7.html)
CN (4) CN105664142A (cg-RX-API-DMAC7.html)
AR (6) AR081681A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012033214B1 (cg-RX-API-DMAC7.html)
CA (1) CA3171308A1 (cg-RX-API-DMAC7.html)
CL (7) CL2012003657A1 (cg-RX-API-DMAC7.html)
DK (3) DK3626258T3 (cg-RX-API-DMAC7.html)
ES (3) ES2858726T3 (cg-RX-API-DMAC7.html)
HK (1) HK1214149A1 (cg-RX-API-DMAC7.html)
HR (3) HRP20211520T1 (cg-RX-API-DMAC7.html)
HU (6) HUE046856T2 (cg-RX-API-DMAC7.html)
LT (3) LT3103469T (cg-RX-API-DMAC7.html)
MX (1) MX354776B (cg-RX-API-DMAC7.html)
NZ (2) NZ702800A (cg-RX-API-DMAC7.html)
PE (8) PE20130578A1 (cg-RX-API-DMAC7.html)
PL (1) PL2588130T3 (cg-RX-API-DMAC7.html)
PT (6) PT3626257T (cg-RX-API-DMAC7.html)
RS (3) RS61683B1 (cg-RX-API-DMAC7.html)
RU (1) RU2761342C2 (cg-RX-API-DMAC7.html)
SI (3) SI3626257T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600385B (cg-RX-API-DMAC7.html)
TW (9) TWI602573B (cg-RX-API-DMAC7.html)
UA (3) UA125743C2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
HRP20190690T1 (hr) 2009-10-09 2019-06-28 Armagen, Inc. Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
SI2585104T1 (sl) 2010-06-25 2019-11-29 Shire Human Genetic Therapies Postopki in sestavki za dostavo arilsulfataze A
HUE046856T2 (hu) 2010-06-25 2020-03-30 Shire Human Genetic Therapies Eljárások és kompozíciók iduronát-2-szulfatáz központi idegrendszerbe történõ leadásához
US20220133863A1 (en) * 2010-06-25 2022-05-05 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
CN103260637B (zh) 2010-06-25 2016-04-06 夏尔人类遗传性治疗公司 乙酰肝素n-硫酸酯酶cns递送的方法和组合物
EP4338797A3 (en) 2011-12-02 2024-06-12 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
BR112014015352A8 (pt) 2011-12-23 2017-06-13 Shire Human Genetic Therapies tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase
CA3209821A1 (en) * 2013-05-15 2014-11-20 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
US10967073B2 (en) 2015-05-07 2021-04-06 The Mclean Hospital Corporation Glucocerebrosidase gene therapy for Parkinson's disease
HK1258054A1 (zh) * 2015-12-30 2019-11-01 株式会社绿十字 用於治疗亨特综合征的方法和组合物
US11345904B2 (en) 2016-02-24 2022-05-31 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
CA3019427A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
JP7449223B2 (ja) 2017-09-22 2024-03-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症ｉｉ型を治療するための遺伝子療法
CA3092218A1 (en) * 2018-02-28 2019-09-06 Seikagaku Corporation Package and method for producing the same
CN108534695A (zh) * 2018-05-04 2018-09-14 无锡恩特卫自动化检测设备有限公司 一种基于机器视觉系统的瓶塞漏酒检测方法及装置
KR102671857B1 (ko) * 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
EP3811962A4 (en) 2018-06-25 2022-03-16 JCR Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
JP7253770B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP7253771B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
KR20230086703A (ko) 2020-10-14 2023-06-15 데날리 테라퓨틱스 인크. 설포글루코사민 설포하이드롤라제 효소를 포함하는 융합 단백질 및 이의 방법
CN113283465B (zh) * 2021-04-02 2022-04-29 电子科技大学 一种弥散张量成像数据分析方法及装置
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途
CN115116623A (zh) * 2022-06-28 2022-09-27 深圳市儿童医院 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端
WO2025054521A1 (en) * 2023-09-07 2025-03-13 Juvena Therapeutics, Inc. Igf2 fusion protein formulations and therapeutic uses thereof
WO2025075929A1 (en) * 2023-10-02 2025-04-10 Neurona Therapeutics Inc. Methods of treating seizure activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043373A2 (en) * 2002-11-07 2004-05-27 Biomarin Pharmaceutical Inc. Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US20090017005A1 (en) * 2003-08-29 2009-01-15 Biomarion Pharmaceutical Inc. Delivery of Therapeutic Compounds to the Brain and Other Tissues

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133001A (en) * 1959-11-26 1964-05-12 Muset Pedro Puig Stabilization of enzymes
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
CA2155005C (en) * 1993-02-02 1999-04-06 Weldon Courtney Mcgregor Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
ATE225184T1 (de) 1997-08-22 2002-10-15 Seikagaku Kogyo Co Ltd Arzneimittel zur behandlung von durch hernie gestörter intervertebraler bandscheibe
ATE410506T1 (de) 1998-12-07 2008-10-15 Genzyme Corp Behandlung der pompeschen krankheit
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US7412285B2 (en) 1999-04-09 2008-08-12 Oncostim, Inc. Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy
US6368315B1 (en) 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US20020099025A1 (en) * 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030040479A1 (en) 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
IL161352A0 (en) 2001-10-16 2004-09-27 Symbiontics Inc Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003068159A2 (en) 2002-02-11 2003-08-21 Wake Forest University Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
JP5570677B2 (ja) 2002-04-25 2014-08-13 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド α−ガラクトシダーゼＡ欠損症の治療
CA2487815A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
EP1426069A1 (en) 2002-12-02 2004-06-09 Diana Evelyn Miller Drug delivery system
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
EP2444102B1 (en) 2003-01-31 2015-04-08 The Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
KR101228204B1 (ko) 2003-02-10 2013-01-31 투-비비비 홀딩 비.브이. 염증성 상태 하에 있는 뇌-혈관 장벽에서 차등 발현되는핵산
CA2525236C (en) 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
US20060029656A1 (en) 2004-02-03 2006-02-09 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
BRPI0507440A (pt) 2004-02-06 2007-07-10 Biomarin Pharm Inc fabricação de enzimas lisossomais altamente fosforiladas e uso das mesmas
US20050244400A1 (en) 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
UA11577U (en) 2004-04-21 2006-01-16 Academician A P Romodanov Inst Device for intrathecal drug administration into spinal canal
KR20070037444A (ko) 2004-06-15 2007-04-04 백스터 인터내셔널 인코포레이티드 고체 미립자성 치료제의 생체외 적용방법
BRPI0514311A (pt) * 2004-08-11 2008-06-10 Ciba Sc Holding Ag indicador de tempo-temperatura à base de enzima
IL165334A0 (en) * 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
JPWO2006121199A1 (ja) * 2005-05-11 2008-12-18 日本ケミカルリサーチ株式会社 脂質小胞体組成物
CN104771402A (zh) 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ES2697502T3 (es) 2006-02-09 2019-01-24 Genzyme Corp Administración intraventricular lenta
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
BRPI0709737A2 (pt) 2006-04-04 2011-07-26 Zymenex As processo para concentraÇço de um polipeptÍdeo
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
US20080076120A1 (en) 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US20080140056A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Method for delivering large molecules to the brain
WO2008109677A2 (en) 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
JP5341756B2 (ja) 2007-06-29 2013-11-13 国立大学法人名古屋大学 神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤
WO2009017005A1 (ja) 2007-07-27 2009-02-05 Sharp Kabushiki Kaisha 移動局装置、基地局装置、通信システム及びプログラム
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
WO2009062348A1 (en) * 2007-11-14 2009-05-22 Institute Of Microbiology, Chinese Academy Of Sciences Methods for inhibiting influenza virus infection and their drugs
TW200938221A (en) 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
PL2245145T3 (pl) 2008-01-18 2017-07-31 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009131698A2 (en) 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
CA2723412A1 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
WO2011163651A2 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
CN103260637B (zh) 2010-06-25 2016-04-06 夏尔人类遗传性治疗公司 乙酰肝素n-硫酸酯酶cns递送的方法和组合物
NZ702801A (en) 2010-06-25 2016-08-26 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
US8545837B2 (en) 2010-06-25 2013-10-01 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
HUE046856T2 (hu) 2010-06-25 2020-03-30 Shire Human Genetic Therapies Eljárások és kompozíciók iduronát-2-szulfatáz központi idegrendszerbe történõ leadásához
SI2585104T1 (sl) 2010-06-25 2019-11-29 Shire Human Genetic Therapies Postopki in sestavki za dostavo arilsulfataze A
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
US8580922B2 (en) * 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
MA40460A (fr) 2014-08-11 2016-02-18 Shire Human Genetic Therapies Ciblage lysosomial et utilisation correspondante
US10722559B2 (en) 2014-08-11 2020-07-28 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
WO2016065319A1 (en) 2014-10-24 2016-04-28 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
US9673835B1 (en) 2015-12-04 2017-06-06 Taiwan Semiconductor Manufacturing Co., Ltd. Pipelined SAR with TDC converter

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043373A2 (en) * 2002-11-07 2004-05-27 Biomarin Pharmaceutical Inc. Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US20090017005A1 (en) * 2003-08-29 2009-01-15 Biomarion Pharmaceutical Inc. Delivery of Therapeutic Compounds to the Brain and Other Tissues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Patricia Dickson et al., Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid, Mol Genet Metab. 2007 May ; 91(1): 61–68. *

Also Published As

Publication number Publication date
JP2020079298A (ja) 2020-05-28
RS62520B1 (sr) 2021-11-30
TW202112391A (zh) 2021-04-01
JP6522073B2 (ja) 2019-05-29
SMT201600385B (it) 2017-03-08
RU2018137304A3 (cg-RX-API-DMAC7.html) 2022-02-22
JP2016040337A (ja) 2016-03-24
CL2020000468A1 (es) 2020-09-04
RU2018137304A (ru) 2019-03-21
CN105664142A (zh) 2016-06-15
US20180085438A1 (en) 2018-03-29
US20220133862A1 (en) 2022-05-05
AR081677A1 (es) 2012-10-10
SI3626257T1 (sl) 2021-12-31
TW202506172A (zh) 2025-02-16
JP2021167340A (ja) 2021-10-21
US12409210B2 (en) 2025-09-09
JP2019031575A (ja) 2019-02-28
TW201212936A (en) 2012-04-01
TWI609694B (zh) 2018-01-01
CL2017002488A1 (es) 2017-12-15
HRP20211520T1 (hr) 2021-12-24
JP6938456B2 (ja) 2021-09-22
JP7543459B2 (ja) 2024-09-02
US20250161417A1 (en) 2025-05-22
US20230026836A1 (en) 2023-01-26
JP2021167341A (ja) 2021-10-21
CL2012003655A1 (es) 2013-04-19
US20180071212A1 (en) 2018-03-15
CL2012003656A1 (es) 2013-07-19
PE20130578A1 (es) 2013-05-19
PE20130589A1 (es) 2013-05-19
JP2017214434A (ja) 2017-12-07
CA3171308A1 (en) 2011-12-29
JP7591476B2 (ja) 2024-11-28
TW201815411A (zh) 2018-05-01
US20250375506A1 (en) 2025-12-11
RS62620B1 (sr) 2021-12-31
TW202337489A (zh) 2023-10-01
TWI669128B (zh) 2019-08-21
JP6797876B2 (ja) 2020-12-09
PE20130579A1 (es) 2013-05-19
RU2017125281A3 (cg-RX-API-DMAC7.html) 2020-11-09
US9220677B2 (en) 2015-12-29
US12161702B2 (en) 2024-12-10
ES2896060T3 (es) 2022-02-23
US20190183984A1 (en) 2019-06-20
PE20130637A1 (es) 2013-06-13
US12121569B2 (en) 2024-10-22
PE20130648A1 (es) 2013-07-03
US11471516B2 (en) 2022-10-18
JP6285409B2 (ja) 2018-02-28
PE20180801A1 (es) 2018-05-09
TW201726161A (zh) 2017-08-01
HUE046856T2 (hu) 2020-03-30
US20200046810A1 (en) 2020-02-13
TW201206465A (en) 2012-02-16
US20230165942A1 (en) 2023-06-01
HRP20211660T1 (hr) 2022-02-04
US12168041B2 (en) 2024-12-17
US20170042977A1 (en) 2017-02-16
RU2017125281A (ru) 2019-01-31
US11065307B2 (en) 2021-07-20
HK1214149A1 (zh) 2016-07-22
US20160158324A1 (en) 2016-06-09
JP2024097029A (ja) 2024-07-17
PE20170938A1 (es) 2017-07-13
LT3103469T (lt) 2021-03-25
JP2016041755A (ja) 2016-03-31
LT3626258T (lt) 2021-12-10
PL2588130T3 (pl) 2017-09-29
HUE046409T2 (hu) 2020-02-28
HRP20210298T1 (hr) 2021-04-16
JP2022024176A (ja) 2022-02-08
PT2585104T (pt) 2019-10-30
PT3103469T (pt) 2021-03-04
US11260112B2 (en) 2022-03-01
CL2016003159A1 (es) 2017-05-12
JP2020079297A (ja) 2020-05-28
JP2016037504A (ja) 2016-03-22
HUE056884T2 (hu) 2022-03-28
JP2019006826A (ja) 2019-01-17
US20140271598A1 (en) 2014-09-18
US20130295077A1 (en) 2013-11-07
ES2858726T3 (es) 2021-09-30
RU2018113327A (ru) 2019-03-01
JP2023052868A (ja) 2023-04-12
RU2761342C2 (ru) 2021-12-07
SI3626258T1 (sl) 2021-11-30
TWI698252B (zh) 2020-07-11
PE20180130A1 (es) 2018-01-18
NZ702800A (en) 2017-03-31
ES2895655T3 (es) 2022-02-22
RU2018113327A3 (cg-RX-API-DMAC7.html) 2021-07-21
AR081679A1 (es) 2012-10-10
CN106139133B (zh) 2020-12-04
PT2593131T (pt) 2019-10-30
US20250121040A1 (en) 2025-04-17
PT2588130T (pt) 2016-11-25
CL2012003654A1 (es) 2013-06-14
US10646554B2 (en) 2020-05-12
CN106139133A (zh) 2016-11-23
UA125743C2 (uk) 2022-06-01
JP2019038853A (ja) 2019-03-14
JP2023099216A (ja) 2023-07-11
RS61683B1 (sr) 2021-05-31
US10456454B2 (en) 2019-10-29
TW201701899A (zh) 2017-01-16
US20200113981A1 (en) 2020-04-16
AR081678A1 (es) 2012-10-10
JP2018002734A (ja) 2018-01-11
UA125060C2 (uk) 2022-01-05
JP6466538B2 (ja) 2019-02-06
JP7359827B2 (ja) 2023-10-11
BR112012033214A2 (pt) 2017-05-23
US20170042978A1 (en) 2017-02-16
JP2021181489A (ja) 2021-11-25
CN104857504A (zh) 2015-08-26
MX2013000321A (es) 2013-04-03
JP7087175B2 (ja) 2022-06-20
PT3626257T (pt) 2021-11-12
TWI876260B (zh) 2025-03-11
JP2020079244A (ja) 2020-05-28
TW201825111A (zh) 2018-07-16
JP6346162B2 (ja) 2018-06-20
HK1218719A1 (zh) 2017-03-10
AR081681A1 (es) 2012-10-10
CN105233277B (zh) 2019-01-01
SI3103469T1 (sl) 2021-04-30
MX354776B (es) 2018-03-20
DK3103469T3 (en) 2021-02-22
JP6522072B2 (ja) 2019-05-29
US9814764B2 (en) 2017-11-14
CL2012003657A1 (es) 2013-04-19
DK3626258T3 (da) 2021-09-20
DK3626257T3 (da) 2021-11-08
JP2016094451A (ja) 2016-05-26
AR082025A1 (es) 2012-11-07
US11065308B2 (en) 2021-07-20
US20200405825A1 (en) 2020-12-31
HUE055963T2 (hu) 2022-01-28
NZ702803A (en) 2017-05-26
HUE031036T2 (en) 2017-06-28
AR081680A1 (es) 2012-10-10
BR112012033214B1 (pt) 2020-11-03
UA129740C2 (uk) 2025-07-23
JP2023062114A (ja) 2023-05-02
JP7448507B2 (ja) 2024-03-12
HUE052944T2 (hu) 2021-05-28
JP2016040335A (ja) 2016-03-24
JP2018002735A (ja) 2018-01-11
CN105233277A (zh) 2016-01-13
JP6250616B2 (ja) 2017-12-20
PT3626258T (pt) 2021-10-19
TWI790444B (zh) 2023-01-21
JP6898909B2 (ja) 2021-07-07
LT3626257T (lt) 2021-12-10

Similar Documents

Publication Publication Date Title
TWI602573B (zh) 溶酶體酵素之腦脊髓膜內遞送及其醫療用途
KR102345973B1 (ko) 치료제들의 cns 전달
TWI546078B (zh) 於腦脊髓膜內遞送乙醯肝素ｎ－硫酸酯酶之方法及組合物
BR112012033205B1 (pt) Uso de uma composição compreendendo agentes terapêuticos para liberação ao sistema nervoso central
HK1218719B (zh) 治疗试剂的cns递送
HK1230954B (en) Cns delivery of therapeutic agents
HK1184712B (en) Cns delivery of therapeutic agents